Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VX-407 | Autosomal Dominant Polycystic Kidney Disease (ADPKD), healthy volunteers | Phase 2 | Enrollment Initiation | oral | Genetic Disorder |
| Vertex Pharmaceuticals Incorporated | VX-993 | Painful diabetic peripheral neuropathy (DPN) | Phase 2 | Enrollment Initiation | Intravenous | Neurology |
| Vertex Pharmaceuticals Incorporated | VX-993 | Moderate to severe acute pain | Phase 2 | Trial Discontinued | Intravenous | Non-Opioid Analgesic |
| Vertex Pharmaceuticals Incorporated | VX-864 | Alpha-1 Antitrypsin Deficiency (AATD) | Phase 2 | Ongoing | Oral | Genetic Disorder |
| Vertex Pharmaceuticals Incorporated | Suzetrigine (VX-548) | Painful diabetic peripheral neuropathy (DPN) | Phase 2 | Ongoing | Oral | Neurology |
| Vertex Pharmaceuticals Incorporated | VX-864 | Alpha-1 antitrypsin (AAT) deficiency | Phase 2 | Trial Discontinued | Oral | Genetic Disorder |
| Vertex Pharmaceuticals Incorporated | VX-147 | Focal segmental glomerulosclerosis (FSGS) | Phase 2 | Trial Completed | oral | #N/A |
| Vertex Pharmaceuticals Incorporated | VX-814 | alpha-1 antitrypsin (AAT) deficiency | Phase 2 | Trial Discontinued | Oral | Genetic Disorder |
